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Abstract
Sudden unexpected death in epilepsy is an unpredicted condition in patients with a diagno-
sis of epilepsy, and autopsy does not conclusively identify cause of death. Although the
pathophysiological mechanisms that underlie this entity remain unknown, the fact that epi-
lepsy can affect cardiac function is not surprising. The genetic factors involving ion channels
co-expressed in the heart and brain and other candidate genes have been previously
described. In the present study, 20 epilepsy patients with personal or family history of heart
rhythm disturbance/cardiac arrhythmias/sudden death were sequenced using a custom re-
sequencing panel. Twenty-six relatives were genetically analysed to ascertain the family
segregation in ten individuals. Four subjects revealed variants with positive genotype-phe-
notype segregation: four missense variants in the CDKL5, CNTNAP2, GRIN2A and
ADGRV1 genes and one copy number variant in KCNQ1. The potential pathogenic role of
variants in new candidate genes will need further studies in larger cohorts, and the evalua-
tion of the potential pathogenic role in the cardio-cerebral mechanisms requires in vivo/in
vitro studies. In addition to family segregation, evaluation of the potential pathogenic roles of
these variants in cardio-cerebral mechanisms by in vivo/in vitro studies should also be per-
formed. The potential pathogenic role of variants in new candidate genes will need further
studies in larger cohorts.
Introduction
Sudden unexpected death (SUDEP) is the sudden, unexpected, witnessed or unwitnessed,
non-traumatic, and non-drowning death in patients with epilepsy, with or without evidence of
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a seizure, with exclusion of documented status epilepticus, and no conclusive cause of death
after a comprehensive medico-legal autopsy[1]. SUDEP is the most common cause of death in
individuals with epilepsy and accounts for 7.5–17% of all deaths[2]. Nevertheless, the incidence
of SUDEP varies widely due to the heterogeneity of the studies (type of epilepsy, size of studied
cohort, definition of SUDEP and how the cause of death was determined)[3]. The risk of
SUDEP is higher in males than in females; however, other risk factors, such as frequency of
tonic-clonic seizures, early age of onset of epilepsy and polytherapy with antiepileptic drugs,
have been identified as risk factors[1, 4]. The pathophysiological mechanisms of SUDEP are
likely multifactorial, but it has been suggested that a specific genetic background may predis-
pose these patients to potentially fatal cardiorespiratory dysfunctions[3]. Indeed, seizures may
induce a variety of transient cardiac effects, which include arrhythmias, asystole and other
heart abnormalities, some of which are potentially lethal[3]. As pathogenic abnormalities in
genes co-expressed in the heart and in the brain may eventually result in SUDEP, several stud-
ies have described pathogenic alterations in genes encoding ion channels in patients with con-
comitant heart conduction disorder and SUDEP[5, 6].
The advent of massive parallel DNA sequencing platforms, referred to as next-generation
sequencing (NGS) technology, has revolutionized the field of medical genomics, enabling fast
and cost-effective generation of genetic data. We previously performed a genetic study in a
large cohort of individuals with epilepsy and cardiac conduction disorders and showed puta-
tive pathogenic disease-causing alterations in genes encoding cardiac ion channels in approxi-
mately 25% of unrelated individuals [7]. However, since SUDEP likely involves some
combination of abnormal brain and cardiac physiology, certain additional gene categories,
e.g., encoding for proteins with a key function of cell excitability, could be suitable candidates
to explain the physiopathology of SUDEP [8].
To test this hypothesis, we used applied NGS analysis to a follow-up cohort of patients with
epilepsy associated with cardiac conduction disorder/SUDEP.
Results
Genetic findings
Nineteen out of the 20 recruited patients carried 56 rare genetic variants in 37 genes. Among
these genetic anomalies, only four variants, i.e., KCNQ1, KCNE1, SCN1A, and CACNA1C,
were previously associated with SUDEP or other disorders associated with sudden cardiac
death (SCD). We also identified 2 CNVs (Fig 1), 45 missense variants, 6 indels and 3 intronic
variants (Table 1).
After the pathogenicity score classification, 3 variants were classified as likely pathogenic,
20 variants were classified as unknown significance, 21 variants were classified as likely non-
pathogenic and 12 variants were classified as benign variants for no segregation within the
family.
Segregation studies were performed in 10 out of 19 SUDEP cases, and a total of 26 relatives
were genetically analysed to ascertain familiar segregation. Four cases showed at least one vari-
ant with positive segregation (ID#1–4), four cases with variants with incomplete penetrance
pattern (ID#5–8) and two cases with negative segregation (ID#18–19). Four subjects, previ-
ously investigated with inconclusive results[9], showed positive segregation (individuals ID#1,
ID#3 and ID#4) or an incomplete pattern of inheritance (ID#5).
Genetic variants in KCNQ1 and CDKL5 genes were identified in ID#1, who had family
members affected by epilepsy and/or long QT syndrome (Fig 2A). While the exon 2 deletion
in KCNQ1 (Fig 1) showed complete segregation with the LQTS, it is unlikely that the CDKL5
variant was causative of the observed epilepsy, as mutations related to this gene typically occur
NGS as genetic diagnosis tool for associated epilepsy and cardiac conduction disorder/SUDEP
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de novo and are associated with early-onset, severe, drug-refractory epileptic encephalopathy
[10].
The variant in the CNTNAP2 gene identified in individual ID# 2 is a novel change classified
as a variant of unknown significance. Segregation studies showed that the non-affected sister
(II:2) and their parents (I:1 and I:2) did not carry this variant (Fig 2B). Heterozygous muta-
tions in CNTNAP2 have been identified in patients with a range of complex phenotypes,
including intellectual disability, autism and schizophrenia [11, 12]. However, heterozygous
CNTNAP2 mutations are also found in the normal population, and it is likely that this variant
alone does not fully explain the patient’s phenotype.
Patient #3 is a 24-year-old woman with family history (individual I:2) of SUDEP. However,
her mother was not available for genetic analysis. Segregation analysis in the non-affected sis-
ters (individuals II:2, II:3) and the father (subject I:1) was inconclusive (Fig 2C).
Individual ID#4 is a 52-year-old man with family history of epilepsy (sister) and sudden
death (his brothers). The variant identified in ADGRV1 is shared by the affected sister (II:2),
but DNA for the deceased brothers was unavailable (Fig 2D).
Individual ID#5 is a 15-year-old boy carrying a novel variant in the TSC1 gene. This variant
was shared by his healthy father (II:3) and affected sister (III:2) with epileptic encephalopathy.
There were antecedents of SCD from the paternal lineage, and the father’s cousins (III:1 and
III:2) were affected by Brugada syndrome (Fig 3A).
Another case with IP was ID#6, a 9-year-old boy affected by SUDEP and Brugada syn-
drome. The non-affected mother (I:2) had family history of Brugada syndrome and showed
the variants in KCNQ2 and SCN1A genes. The variant in the SCN1A gene was also present in
the non-asymptomatic sister (II:2) (Fig 3B).
ID#7 is a 16-year-old boy affected by focal epilepsy and LQTS and carrying a rare genetic
variant in ADGRV1 that was harboured by his healthy mother (I:2) (Fig 3C).
Finally, ID#8 is a 21-year-old girl who suffered focal epilepsy and SUDEP. She carried six
rare genetic variants in BRD2,NRXN1, SCARB2, POLG, HTR3B, and SCN1A. The brother’s
Fig 1. A: Deletion of exon 2 of the KCNQ1 gene in ID#1. B: Duplication of exon 4 of the CNTNAP2 gene in ID#15.
https://doi.org/10.1371/journal.pone.0189618.g001
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Table 1. Rare genetic variants identified in our cohort.
Patient
ID
Gene Protein/cDNA variant Variant Code MAF (All) In silico Segregation Pathogenicity Score
Positive segregation
1a KCNQ1 exon 2 deletion - - - Yes Likely pathogenic
KCNE1 p.Arg98Trp (c.292C>T) rs199473362,
CM002283
1.653x10-5 PD/D/
DC
No Benign
HTR2A p.Ile206Val (c.616A>G) - - N/DC/
DC
No Benign
SENP2 p.Ser231Cysfs*43 (c.692-693delCT) - - - No Benign
CDKL5 p.Arg914Lys (c.2741G>A*) - - B/N/P Yes VUS
CACNA1H p.Thr78Ala (c.232A>G) - - B/N/P No Benign
2 CNTNAP2 p.Ser339Asn (c.1016G>A) - - N/DC/
DC
Yes VUS
3a GRIN2A p.Asn1076Lys (c.3228C>A) rs61758995 0.004349 PD/N/
DC
Yes Likely non-
pathogenic
CACNA1A p.His2216_His2217insHis (c.
ins6646_6648insCAC)
- - - IP VUS
ADSL p.Asp430Asn (c.1288G>A) rs554254383,
CM001054
1.647x10-5 IP VUS
ADGRV1 p.Met1179Leu (c.3535A>T) rs759416461 8.292x10-6 B/N/P IP Likely non-
pathogenic
4a PLCB1 p.Ala10Ser (c.28G>T) rs150241349 0.0003402 PD/N/
DC
No Benign
ADGRV1 p.Glu3215Lys (c.9643G>A) rs199499672 0.0003396 PD/D/
DC
Yes VUS
Incomplete penetrance
5a TSC1 p.Ser108Phe (c.323C>T) - - PD/D/
DC
IP VUS
6 CELSR1 p.Ala16_Ala17insAla (c.46_48insGCC) - - - No Likely non-
pathogenic
KCNQ2 p.Val450Met (c.1348G>A) rs146492238 0.001265 B/N/P IP VUS
HTR5A p.Pro95Leu (c.284C>T) rs144847277 8.355x10-
6
PD/D/
DC
No Likely non-
pathogenic
SCN1A p.Arg1334Met (c.4001G>T) - - PD/D/
DC
IP Likely pathogenic
7 ADGRV1 p.Arg4770His (c.14309G>A) - - B/N/P IP Likely non-
pathogenic
8a BRD2 p.Ala599Pro (c.1795G>C) rs55952113 0.004153 B/N/P IP Likely non-
pathogenic
NRXN1 c.1278+5A>T rs201802152 0.002269 - IP Likely non-
pathogenic
SCARB2 p.Glu93Lys (c.277G>A) rs145870223 0.0001573 PD/D/
DC
No Benign
POLG p.Lys512Arg (c.1535A>G) - - B/N/P No Benign
HTR3B p.Ser156Arg (c.466A>C) rs72466469, CM083528 0.004127 PD/N/
DC
No Benign
SCN1A p.Arg1928Gly (c.5782C>G) rs121917956,
CM081420
0.001427 B/N/DC No Benign
No available relatives
9 CACNA1H p.Met2312Val (c.6934A>G) - 0.001677 B/N/P NA VUS
SLC2A1 p.Arg400Cys (c.1198C>T) - - PD/D/
DC
NA VUS
ADGRV1 p.Thr879Met (c.2636C>T) rs201007778 0.0001631 PD/D/
DC
NA Likely non-
pathogenic
MBD5 p.Pro721Leu (c.2162C>T) rs138639760 0.0001982 B/N/DC NA Likely non-
pathogenic
SCN2A c.605+3A>G rs778554811 - - NA VUS
(Continued)
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Table 1. (Continued)
Patient
ID
Gene Protein/cDNA variant Variant Code MAF (All) In silico Segregation Pathogenicity Score
10 CACNA1C p.Val1707Ile (c.5119G>A) rs147896322 - PD/N/
DC
NA VUS
HTR2A p.Ala447Val (c.1340C>T) rs6308, CM115490 0.001484 B/N/P NA Likely non-
pathogenic
PNKP c.1029+2T>C rs199919568 0.0006509 - NA Likely non-
pathogenic
CACNA1I p.Asp2040Tyr (c.6118G>T) rs771105041 0.004771 PD/D/P NA Likely non-
pathogenic
11 HCN2 c.2143_2145delCCG rs527536363 - - NA VUS
CACNA1H p.Ala1570Val (c.4709C>T) rs558718048 5.014x10-
5
PD/D/
DC
NA VUS
12 ADGRV1 p.Pro4181Leu (c.12542C>T) rs200957385 - B/D/DC NA Likely non-
pathogenic
KCNQ3 p.Pro574Ser (c.1720C>T) rs74582884, CM083709 0.001995 PD/N/
DC
NA Likely pathogenic
13 CACNA1A p.2319Gln_2320GlninsGln
(c.6955_6957insCAG)
- - - NA VUS
BRD2 p.Asn194Lys (c.582C>G) rs201572264 7.753x10-
5
B/N/DC NA Likely non-
pathogenic
ADGRV1 p.Val754Ala (c.2261T>C) rs374609813 - PD/N/
DC
NA Likely non-
pathogenic
HTR3B p.Gln334Glu (c.1001G>A) rs199833563 8.238x10-
6
B/N/P NA Likely non-
pathogenic
14 CACNA1A p.Gln2326_Gln2331del (c.6976_6993del18) rs765169827 - - NA VUS
SCARB2 p.Val149Met (c.445G>A) rs147159813 0.002053 B/N/P NA Likely non-
pathogenic
CNTNAP2 exon 4 duplication - - - NA VUS
15 CACNA1I p.Arg1448Gln (c.4343G>A) rs201480163 9.944x10-
5
PD/D/
DC
NA VUS
16 GRIN2B p.Lys1090Arg (c.3269A>G) - - PD/D/
DC
NA VUS
HTR7 p.Lys445Asn (c.1335G>C) rs138700544 - B/N/P NA Likely non-
pathogenic
CHRNB2 p.Phe472Ser (c.1415T>C) rs200855905 4.118x10-
5
PD/N/
DC
NA Likely non-
pathogenic
17 ADGRV1 p.Glu2897Asp (c.8691A>C) rs201586455 0.004302 PD/N/
DC
NA Likely non-
pathogenic
No segregation
18 TBC1D24 p.Glu94Lys (c.280G>A) - - PD/D/
DC
No Benign
ADSL p.Asp215Asn (c.643G>A) - - PD/D/
DC
No Benign
KCNMA1 p.Val792Ile (c.2374G>A) rs142770262 - B/N/DC No Benign
19 CACNA1H p.Ala2208Val (c.6623C>T) rs777217625 - B/N/P No VUS
EFHC1 p.Arg42Pro (c.125G>C) rs773598517 - B/N/DC No VUS
ATP1A2 p.Arg3His (c.8G>A) rs781687346 8.12x10-5 PD/N/P No Likely non-
pathogenic
NA: DNA not available from relatives. IP: Incomplete penetrance. CM: Human gene variation database code. MAF: Minor allele frequency in the ExAG (Last
consulted May 2016). In silico predictors were PolyPhen2, Provean and Mutation Taster. N: Neutral; D: Deleterious; P: Polymorphism; DC: Disease
causing; B: Benign; PD: Possibly damaging; VUS: Variant of uncertain significance.
*Variant detected in homozygous state.
aSUDEP cases sequenced in a previous custom resequencing panel.
https://doi.org/10.1371/journal.pone.0189618.t001
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father (II:1) died from sudden death and the mother’s sister (II:4) experienced SUDEP. Her
healthy mother (II:3) carried the variants in the BRD2 and SCARB2 genes. Thus, segregation
analysis in this family was also inconclusive (Fig 3D).
Fig 2. Pedigrees of the families with variants showing complete segregation (ID#1–4).
https://doi.org/10.1371/journal.pone.0189618.g002
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There were two index cases with rare genetic variants not showing segregation with the
pathology. ID#19 carried three variants in the ADSL, TBC1D24, and KCNMA1 genes, but his
dead brother (II:1) did not harbour any of these variants (Fig 4A). Patient ID#20 is a 12-year-
Fig 3. Pedigrees of the families with variants showing an incomplete pattern of inheritance (ID#5–8).
https://doi.org/10.1371/journal.pone.0189618.g003
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old boy with focal epilepsy, and her brother (II:1) died of SUDEP while asleep at age 11 years.
The maternal uncle has a 9-year-old child (II:3) who suffered a single seizure. Three rare
genetic variants were identified in the index case, but only two of these variants (EFHC1 and
CACNA1H) were derived from the maternal lineage. However, these variants were absent in
the deceased brother (II:2) (Fig 4B).
Discussion
Sudden unexpected death is a catastrophic complication of human epilepsy with an incidence
of 6.3–9.3 per 1,000 person years in epilepsy patients entering surgery programmes [1].
Despite recent advances, both cellular mechanisms and genetic bases remain largely unknown.
A leading hypothesis suggests a dysfunction of excitability that could underlie both epilepsy
and cardiac arrhythmias, leading to death [13]. Recently, there has been increased interest in
the potential association between epilepsy channelopathies and cardiac arrhythmias [5–7].
NGS is a fast and cost-effective method for the simultaneous detection of single nucleotide var-
iants (SNVs) and small insertions or deletions (indels). Various studies have employed massive
Fig 4. Pedigree of the family with variants that did not show segregation (ID#18–19).
https://doi.org/10.1371/journal.pone.0189618.g004
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sequencing technology to identify new potential genes responsible for SUDEP[9, 14]. Olson
et al. identified several CNVs with causative roles in some cases of paediatric epilepsy, suggest-
ing that these types of variations may potentially be associated with SUDEP cases[15]. We per-
formed a comprehensive genetic analysis using NGS technology to further explore the role of
already known and novel candidate genes associated with epilepsy/SUDEP.
The first index case (ID#1) evidenced the coexistence of both LQTS and epilepsy. The exon
2 deletion showed positive segregation with the LQTS and the mutation in the CDKL5 gene
with the epilepsy in this family. Deletions in KCNQ1 exons were previously reported by NGS
in individuals with LQTS [16]. The CDKL5 gene acts as a kinase, and one of its target proteins
is MeCP2, which plays important roles in the function of nerve cells (neurons) and other brain
cells and in the maintenance of connections (synapses) between neurons. Pathogenic variants
in the CDKL5 gene have been associated with a disorder known as X-linked infantile spasm
syndrome, which is characterized by recurrent seizures called infantile spasms that begin in
the first year of life and with intellectual disability; however, it is not clear how mutations in
this gene can result in this phenotype [10].
In ID#2 we detected a novel rare variant in the CNTNAP2 gene (contactin associated pro-
tein-like 2). Pathogenic alterations in this gene were associated with cortical dysplasia focal
epilepsy syndrome, a rare disorder resulting in epileptic seizures, language regression, intellec-
tual disability, hyperactivity and autism in nearly two-thirds of the patients[11]. However, vari-
ants in this gene have been found in control populations, whereas homozygous variants are
rare in patient populations and have not been found in any unaffected individuals[12].
Although the father was affected by Brugada syndrome (BrS) and epilepsy and carried this var-
iant, the absence of this complex phenotype and the lack of expression of the CNTNAP2 gene
in the heart complicate the association between this variant and SUDEP.
Individual ID#3 carried four rare genetic variants, and only variants with positive segrega-
tion were detected in the GRIN2A gene, although pathogenic score classified as probably no-
pathogenic variant. Mutations in this gene have been associated with focal epilepsies as the
phenotype of our index case.
The variant with positive segregation in the ID#4 was identified in the ADGRV1 gene also
known as GPR98 (MASS1 gene). The encoded protein contains a 7-transmembrane receptor
domain, binds calcium and was expressed in the central nervous system. Pathogenic alter-
ations in this gene have been associated with recurrent febrile seizures and afebrile seizures
[17].
The variant identified in the ID#5 was in TSC1 gene, which encodes for hamartin, a protein
that interacts with tuberin and helps to control cell growth and size through the mTOR path-
way[18]. Mutations in this gene are responsible for Tuberous sclerosis complex (TSC) and
focal cortical dysplasia associated with drug-resistant epilepsy. Although the proband does not
have a phenotype compatible with TSC, the role of hamartin deserves additional investigation
due to its high expression in heart muscle [19].
The KCNQ2 variant identified in individual ID#6 and the non-affected mother belongs to a
large family of genes encoding potassium channels associated with benign neonatal seizures
[20], but the role of this variant in the BrS phenotype of this family remains unclear. Con-
versely, SCN1A is a good gene candidate associated with a large range of epileptic phenotypes
as well as cardiac dysfunction [21].
The variant identified in the ADGRV1 gene of ID#7 is present in the non-affected mother,
and no family history of epilepsy or LQTS is known. Mutations in this gene have been associ-
ated with Usher’s syndrome and febrile seizures familiar 4 (FEB4) and was not expressed in
the heart, indicating that this variant was more related to epilepsy than to LQTS in this family
NGS as genetic diagnosis tool for associated epilepsy and cardiac conduction disorder/SUDEP
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[22]. Genetic testing of the main and associated genes related to LQTS would be the next strat-
egy to identify the genetic cause of the disease in this patient.
The last genes with IP with the diseases were detected in ID#8. The non-affected mother
carried variants in the BRD2 and SCARB2 genes, which could explain the SUDEP in her sister.
Mutations in both genes have been associated with myoclonic epilepsy[23, 24]. SCARB2 gene
encodes for LIMP-2 protein, which is found in the heart, specifically in the intercalated discs,
although its precise function is not clear[22].
Pathogenic variants in the genes identified in the present cohort were previously associated
with syndromes involving intellectual disabilities with episodes of seizures difficulty the possi-
ble relation with SUDEP. However, ion channel genes, such as calcium (GRIN2A), potassium
(KCNQ2) or sodium (SCN1A) channels, may represent interesting candidate genes that under-
lie SUDEP, as the expression and regulation of these genes contributes to the central control of
cardiac and respiratory function.
Conclusion
Rare genetic alterations in genes encoding brain/heart ion channels are responsible for epi-
lepsy associated with cardiac conduction disorder/SUDEP. NGS technology enables the
comprehensive cost-effectives genetic analysis of all current known genes as well as candi-
date genes. Overall, we identified 5 rare genetic variants that segregated within the pedigree
and explain the cardiac conduction disorder/SUDEP. Only one variant was a previously
described gene, revealing four new potential genes associated with this entity. The new cus-
tom re-sequencing panel enabled the identification of potential pathogenic variants in three
out of four negative SUDEP cases in a previous study. Genetic data should be interpreted by
a group of experts, and translation into clinical and forensic fields should be done with
caution.
Methods
Patients
The present study is a follow-up study in patients with clinical and EEG features consistent
with a diagnosis of non-lesional (MRI-negative) focal or generalized epilepsy and a personal or
family history of heart rhythm disturbances/cardiac arrhythmias/sudden death (Table 2).
DNA samples of relatives were obtained when available to ascertain the segregation of each
genetic variant. All patients received at least one surface electrocardiogram (EKG), which was
evaluated by an expert cardiologist. Vague histories of heart rhythm disturbances in family
members not clearly known by the proband or with any available clinical/instrumental data
were excluded.
Each proband was genetically evaluated by target re-sequencing of exonic and intron-exon
boundary regions. Clinical data and DNA from available relatives were obtained for testing in
segregation studies of the rare genetic variants. The four SUDEP cases included in this cohort
were genetically negative in a previous published SUDEP study [9].
All individuals and their family members signed a written informed consent to participate
in the present study in accordance with the guidelines of the International Review Board of
Catholic University. The study was approved through the Ethics Committee of Catholic Uni-
versity (Rome, Italy) in accordance with the principles outlined in the Declaration of Helsinki.
The Full name of Ethic Committee is “Ethics Commitee, Università Cattolica del Sacro Cuore
Largo Agostino Gemelli 8, 00168 Roma, Italy. The individuals in the present study provided
written informed consent (as outlined in PLOS consent form) to publish these case details.
NGS as genetic diagnosis tool for associated epilepsy and cardiac conduction disorder/SUDEP
PLOS ONE | https://doi.org/10.1371/journal.pone.0189618 December 19, 2017 10 / 16
DNA samples
Genomic DNA was extracted from whole blood or saliva with Chemagic MSM I, and the con-
centration was checked by fluorometry (Qubit, Life Technologies). DNA integrity was assessed
on a 0.8% agarose gel.
NGS studies
We designed a custom resequencing panel, which included 122 genes associated with epilepsy
as well as the main genes associated with cardiac channelopathies (S1 Table). The final size was
487.874 kbp of encoding regions and UTR boundaries. We targeted one isoform for each gene
and only coding exons plus 10 bp inside intronic regions. Exons were obtained from ensembl
site[25] version 81 in GRCh38 and translated to hg19. Bait design was achieved using an in-
house algorithm and submitted to Agilent SureSelect Design Web. The chip design was
achieved using variable tailing bait and variable multiplicity bait to obtain homogeneous cover-
age and optimize sample load. The present bait design algorithm considers the GC content of
the bait itself, and the target and surrounding region of the targeted gene. This algorithm also
considers multimapping of the bait regions and uses, when available, previous NGS results.
Genomic DNA was fragmented by sonication using the Bioruptor (Diagenode). The 122
genes were enriched using the SureSelect Custom Target Enrichment System Kit (Agilent
Technologies, Santa Clara, CA USA) according to the manufacture’s instructions for the "Sure-
Select Target Enrichment System for Illumina Paired-End Sequencing version B.1” (SureSelect
XT Custom 0–499 kbp library, Agilent Technologies, Inc.). The paired-end sequencing process
was developed on a MiSeq System (Illumina) using 2x76 bp reads length.
Table 2. Clinical data for the investigated cohort.
Proband ID Age (y) Gender Epilepsy type (onset, y) Cardiac comorbidity Tested family members (n) Segregating variant(s)
1 32 Male Focal epilepsy (24) LQTS 4 2/6
2 31 Male Focal epilepsy (21) SUDEP 3 1/1
3 24 Female Focal epilepsy (11) SUDEP 3 1/4
4 52 Male Focal epilepsy (43) SUDEP 1 1/2
5 15 Male Focal epilepsy (7) SUDEP 3 0/1
6 9 Male Generalized epilepsy (6) SUDEP 2 0/4
7 16 Male Focal epilepsy (11) LQTS 2 0/1
8 21 Female Focal epilepsy (17) SUDEP 2 0/6
9 13 Female Generalized epilepsy (12) CPVT NA NA
10 26 Female Focal epilepsy (26) SUDEP NA NA
11 22 Female Focal epilepsy (22) SUDEP NA NA
12 25 Male Generalized epilepsy (14) SUDEP NA NA
13 21 Male Generalized epilepsy (16) SUDEP NA NA
14 13 Male Generalized epilepsy (12) SUDEP NA NA
15 19 Male Focal epilepsy (17) SUDEP NA NA
16 23 Female Focal epilepsy (20) SUDEP NA NA
17 17 Male Generalized epilepsy (14) SUDEP NA NA
18 23 Male Focal epilepsy (20) SUDEP 3 0/3
19 12 Male Focal epilepsy (10) BS 3 0/3
20 12 Male Focal epilepsy (8) SUDEP NA NA
NA: DNA not available from relatives. Familial individual tested excluding the proband. Variant/s segregated indicates the number of variants showing a
complete segregation/total of the variants identified in the proband.
https://doi.org/10.1371/journal.pone.0189618.t002
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Data analysis
NGS analysis was submitted to the GendiCall Pipeline (Gendicall Software from FerrerIn-
code), which cleans up and trims fastq files from sequencer and then Gendicall maps using
either GEM[26] or BWAmapper[27]. Subsequently, bam was generated and sorted, and dupli-
cates were removed with Picard (http://picard.sourceforge.net). Variant call for SNVs and
Small Indels were performed using Samtools (v.1.3.1)[28] and internal Gendicall Caller. Anno-
tation of called variants was based on several sources, and for population data, we used dbSNP
[29], 1000 Genomes Project[30], Exome Variants Server (EVS)[31] and Exome Aggregation
Consortium (ExAC) Cambridge, MA (URL: http://exac.broadinstitute.org). The protein pre-
dictors used in the present study were Polyphen2[32], Provean[33] and Mutation Taster[34].
Finally, we also used the splicing predictors MaxEntScan[35], FSPLICE[36], GeneSplicer[37]
and NNsplice[38].
Validation and bioinformatics analysis
The variants with MAF (minor allele frequency) lower than 0.1 (<1%) were assessed in locus-
specific databases that include dbSNP[29], Ensembl genome browser[25], the 1000 Genomes
Project[39], EVS (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seat-
tle, WA (URL: http://evs.gs.washington.edu/EVS/) [date (July, 2017) accessed] and ExAC[40].
Rare single nucleotide variants (SNPs) and insertions/deletions (indels) were confirmed by
conventional Sanger sequencing, and copy number variants (CNVs) were confirmed by a mul-
tiplex ligation-dependent probe amplification (MLPA) technique.
Rare genetic variants and sequence regions with coverage lower than 30X were validated by
the Sanger method. First, polymerase chain reaction (PCR) was performed, and the product
was purified by ExoSAP-IT (USB Corporation, Cleveland, OH, USA) and directly sequenced
by the dideoxy chain-termination method in ABI Prism Big Dye1 Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, USA). Sequencing was processed in a 3130XL Genetic
Analyzer (Applied Biosystems) and analysed by SeqScape Software v2.5 (Life Technologies),
comparing the obtained results with the reference sequence from hg19. Protein numbering
reflects the translation initiator methionine as +1.
The CNVs detected by NGS were confirmed by MLPA (MRC-Holland, Amsterdam, Neth-
erlands) with the corresponding probe mix SALSAMLPA: SALSAMLPA P114 Long-QT
probe mix and SALSAMLPA P297 Microdeletion Syndromes-2 probe mix. The MLPA DNA
detection and quantification were performed according to the manufacturer’s protocol
(MRC-Holland, Amsterdam, Netherlands). After the multiplex PCR reaction, electrophoresis
was performed using the ABI3130xl Genetic Analyzer (Applied Biosystems, CA, USA), and
the data were analysed with Coffalyser.net software (MRC-Holland). Significantly (30%)
decreased or increased signals in the patient sample relative to controls were considered as
deletions or duplications, respectively. Familial segregation of CNVs was also performed using
MLPA. Variant frequencies (minor allele frequency, MAF>1%) were obtained from the ExAC
collection (http://exac.broadinstitute.org/).
A pathogenicity score was assigned to each variant for classification into the following cate-
gories: pathogenic, likely pathogenic, variant of unknown significance, likely non-pathogenic
and benign, as described[41]. In silico analysis of the pathogenicity of rare nonsynonymous
variants was performed by Polyphen2, Provean and MutationTaster [42–44].
Limitations
The present study has primary limitations. First, the lack of family segregation impedes the
proper classification of the potential pathogenic role of each variant, and consequently,
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translation into clinical and forensic practice should be implemented with caution. In addi-
tion, functional in vivo/in vitro studies should also be performed to unravel the cellular mecha-
nisms involved in SUDEP. We cannot exclude that these patients carry a genetic alteration in
other genes that were not included in the present genetic panel. In these negative cases, and
if the relatives are available, whole-exome sequencing studies could be a proper approach.
Finally, additional studies in large cohorts should be performed to corroborate these results
and identify new genetic alterations; however, the low incidence of SUDEP complicates sample
collection.
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